Alvotech has delivered on indications that it would look to collaborate on certain biosimilar opportunities in future, striking a licensing deal with BiosanaPharma that will see the two firms partner to co-develop an omalizumab biosimilar rival to Xolair.
Alvotech has delivered on recent indications that it would look to use in-licensing deals to supplement its in-house biosimilars pipeline, striking a licensing deal with BiosanaPharma that will see the two companies collaborate on co-developing a rival to Novartis/Genentech’s Xolair (omalizumab) asthma and spontaneous urticaria treatment.
The exclusive global licensing agreement will see Alvotech and BiosanaPharma co-develop the AVT23 candidate – also referred to under the...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
